ASSessment of Left Ventricular Function Using 12-lead ECG and Cardiac Troponin-T in Correlation with 2D-Echo Following New-onset Myocardial Infarction

Peddi Bhaskar1, Bikshapathi Rao2, Naveen3

1Associate Professor, Department of Medicine, KMC/MGM Hospital, Warangal Dist., Telangana.
2Associate Professor, Department of Medicine, KMC/MGM Hospital, Warangal Dist., Telangana.
3Postgraduate, Department of Medicine, KMC/MGM Hospital, Warangal Dist., Telangana.

ABSTRACT
Left ventricular function is the best individual predictor of mortality after acute myocardial infarction. After Acute Myocardial Infarction (AMI), a patient’s prognosis is closely related to the extent of irreversibly damaged myocardium. The evaluation of infarct size after Acute Myocardial Infarction (AMI) is important for predicting the subsequent clinical course and to validate the effectiveness and clinical relevance of therapeutic interventions.

REVIEW OF LITERATURE
Coronary artery disease is the leading cause of death worldwide. The global burden of cardiovascular disease is expected to increase in the coming years, as falling mortality rates from coronary artery disease in the Western world are more than offset by the continuing epidemiological transition in developing countries away from nutritional deficiencies and infectious disease towards chronic and degenerative pathologies, cardiovascular disease being the most prominent.

MATERIALS AND METHODS
The study was carried out in a study group of consecutive 88 patients admitted in ICCU from March 2012 to August 2013 in the Department of Medicine of MAHATMA GANDHI MEMORIAL HOSPITAL, Warangal, satisfying the selection criteria (as per inclusion and exclusion criteria laid down).

RESULTS
The study was carried out in a study group of consecutive 88 patients admitted in ICCU from March 2012 to August 2013 in the Department of Medicine of MAHATMA GANDHI MEMORIAL HOSPITAL, Warangal, satisfying the selection criteria (as per inclusion and exclusion criteria laid down).

CONCLUSION
Serum troponin T concentration has a strong negative correlation with left ventricular ejection fraction after first acute myocardial infarction and hence can be used to assess the LVEF in patients with first myocardial infarction. A level of >3.24 μg/mL provided a good indication for LVEF below 50% with a sensitivity of 91.67% (CI 80 to 97.7) and specificity of 92.5% (CI 79.6 to 98.4) and thus can identify patients with higher risk.

KEYWORDS
Acute Myocardial Infarction.


INTRODUCTION
Left ventricular function is the best individual predictor of mortality after acute myocardial infarction. After Acute Myocardial Infarction (AMI), the patient’s prognosis is closely related to the extent of irreversibly damaged myocardium. The evaluation of infarct size after Acute Myocardial Infarction (AMI) is important for predicting the subsequent clinical course and to validate the effectiveness and clinical relevance of therapeutic interventions.

Quantitative histologic estimates of infarct size are regarded as the gold standard, but the method has little clinical relevance. It is desirable to find a simple and reliable method with which to quantify infarct size. Various methods such as electrocardiography, echocardiography, left ventriculography, radionuclide-based measurements and the release of cardiac biomarkers have been proposed.

In clinical practice, the extent of injury to the myocardium after AMI is generally assessed by creatine kinase MB isoenzyme (CK-MB) release curves using serial serum sampling. Although quantitative calculations based on the area under the CK-MB vs. time curve are seldom made, many physicians use peak CK-MB to get a qualitative estimate of the size of the infarct. The well-known limitations of CK-MB measurements, such as the short duration of increase after AMI, the requirement for repetitive, frequent sampling for evaluation of peak concentrations, the sensitivity to reperfusion status and the lack of specificity for cardiac damage have stimulated the search for a more suitable biomarker for sizing infarcts. Cardiac troponin T (cTnT) is a cardiac-specific protein...
that is compartmented in the contractile apparatus of the myocardial cell. Its release process into the blood after myocardial injury is slow (cTnT is present in plasma for more than 120 hrs. after AMI), and it is only slightly affected by reperfusion of the infarct zone. For these reasons, plasma cTnT has been used for estimation of infarct size.

The cardiac Troponin T (cTnT) has been found to have excellent sensitivity and specificity and is superior to creatine kinase–MB (CK–MB) as an indicator of myocardial necrosis. cTnT is uniquely located in the myocardium and its release closely relates to infarct size; therefore, inversely correlates with left ventricular ejection fraction (LVEF). We performed this study to find out the level of cTnT after AMI, and its correlation with LVEF.

The 12-lead Surface Electrocardiogram (ECG) is cheap, safe, quick, universally available and well-tolerated by patients. The Selvester QRS score can be applied to the 12-lead ECG once the acute ST-segment deviation has resolved to estimate infarct size in both anterior and inferior ventricular locations. From the QRS score, the LVEF can be estimated. Both the QRS score and the subsequent LVEF calculation were however derived in non-reperfused infarcts. Several studies in reperfused infarcts have shown significant correlations between the QRS score, radionuclear perfusion defects and echocardiographic dyssynergy indices. The ECG QRS scoring included the complete 50-criteria, 32-point Selvester scoring system that has been previously reported and validated.

In this study, we applied the QRS score to patients surviving a first acute myocardial infarction. The purpose of the study was to compare the QRS score with left ventricular ejection fraction, relate the score to clinical and biochemical estimates of LVEF.

Coronary artery disease is the leading cause of death worldwide. The global burden of cardiovascular disease is expected to increase in the coming years as falling mortality rates from coronary artery disease in the Western world are more than offset by the continuing epidemiological transition in developing countries away from nutritional deficiencies and infectious disease towards chronic and degenerative pathologies, cardiovascular disease being the most prominent.

Acute MI is a serious and potentially lethal manifestation of coronary artery disease affecting more than 7 million people worldwide each year. James Herrick established MI as a distinct clinical entity in 1912 and also installed the mainstay management strategy – which prevailed for the next 50 years - in stressing the importance of “absolute bed rest.” Thanks to a remarkable scientific journey throughout the last 60 years – spanning epidemiology, basic science and clinical trials – such long-held beliefs are now considered obsolete; and a comprehensive, continually evolving evidence base has been generated from which contemporary preventive and therapeutic strategies have been developed.

Beginning in the late 1940s, prospective studies were designed to define lifestyle, environmental and other factors contributing to the incidence of MI. In the 1960s, designated coronary care units were established in many hospitals to monitor AMI patients and ensure prompt resuscitation in the event of life-threatening arrhythmias. A development called the “single most important advance in the treatment of acute MI.” These significant progressions were then augmented by basic science studies elucidating many of the key underlying mechanisms of AMI, which paved the way for landmark clinical trials spanning from acute interventions such as reperfusion therapy to long-term pharmacological therapies that are now cornerstones in the management of AMI patients. The combined impact of these preventive and therapeutic measures has resulted in large reductions in mortality following AMI in the developed world.

In STEMI, the last innovation to provide clear-cut incremental benefit has been the introduction of PCI. When delivered in a timely fashion, PCI reduces early death, re-infarction and stroke compared to pharmacological reperfusion by fibrinolysis. Further therapeutic innovations and effective preventive strategies are still being pursued. Among these are efforts to protect the ischaemic myocardium against reperfusion injury. Reperfusion injury refers to tissue damage occurring as a consequence of blood supply being re-established after a period of ischaemia. Mitigation of reperfusion injury has been demonstrated in animal models, but proved difficult to replicate in clinical studies. Several approaches have been tested, but none have yet demonstrated efficacy in pivotal clinical trials. The FIRE (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial from which database thesis is based, also failed to replicate experimental findings in a clinical setting. The concept of post-conditioning has emerged as one of the most promising strategies to confer cardio-protection in the setting of reperfusion. It is currently being evaluated in multiple randomised trials. So far results have been encouraging, but benefits may be restricted to patients with large infarctions.

Despite the significant improvements in prognosis, a gradient of risk still exists following AMI and risk stratification remains crucial to allocate resources efficiently, optimise patient outcomes and limit adverse events. Particularly, early identification of high-risk patients with extensive myocardial injury is important to ensure appropriate administration of pharmacotherapies and prophylactic interventions.

**MATERIALS AND METHODS**

The study was carried out in a study group of consecutive 88 patients admitted in ICU from March 2012 to August 2013 in the Department of Medicine of MAHATMA GANDHI MEMORIAL HOSPITAL, Warangal, satisfying the selection criteria (as per inclusion and exclusion criteria laid down).

**Inclusion Criteria**

Patients who satisfy the WHO criteria for the diagnosis of acute MI are included.

- A history of ischaemic type of chest pain,
- Evolutionary changes on serially obtained ECG tracings, and
- A rise and fall in serum cardiac markers.

**Exclusion Criteria**

Patients Presenting with,

- Previous history of MI
- LVH, intraventricular conduction defects and complete heart blocks
- Valvular heart disease
- Cardiomyopathy
- Pericardial diseases
Congenital heart disease
Previous cardiac surgeries, and
Renal failure were excluded from the study.

No control subjects were taken, because cTnT is not detected in the peripheral circulation under normal circumstances.

Serum troponin-T concentration was measured between 12-48 hours after the onset of chest pain.

Standard 12-lead electrocardiograms were recorded at a 25 mm paper speed for the patients who met the preceding entry criteria had a QRS score calculated from the discharge electrocardiogram on the basis of Q and R wave duration and R to Q and R to S amplitude ratios.

Echocardiograms were obtained using an echocardiographic machine, a 3.5 MHz multiphase array probe in subjects lying in the left lateral decubitus position and supine position.

The echocardiographic techniques and calculations of different cardiac dimensions were performed according to the recommendations of the American Society of Echocardiography. The ejection fraction was obtained using an M Mode method from apical four chamber view. Measurements were made from three consecutive beats and the average of three beats was used for analysis. LVEF less than 50% was taken as systolic dysfunction.

The relation between LVEF and cTnT concentration; LVEF and QRS score was studied using Pearson’s correlation coefficient and by systemic analysis of sensitivity and specificity.

Patients were initially categorised into two data sets, those with EF < 50% and those with EF > 50%. Fisher’s exact test or linear regression analysis were applied when appropriate. The most advantageous cut-off values to predict mortality were selected from visual inspection of the Receiver-Operator Characteristic curves (ROC).

RESULTS
The study was carried out in a study group of consecutive 88 patients admitted in ICU from March 2012 to August 2013 in the Department of Medicine of MAHATMA GANDHI MEMORIAL HOSPITAL, Warangal, satisfying the selection criteria (as per inclusion and exclusion criteria laid down).

Mean age of the patients in present study was 52±12. Most of the patients in our study were in age group 41-60 yrs. (82.5%); 66.6% of patients were male and only 36.3% were female; 67% of patients had AWMI and 33% patients had IWMI, 60% patients had dyslipidaemia. It was found to be most common risk factor. Hypertension (57%) and Diabetes (42%) were other significant risk factors, mainly in male patients. Risk factors were much more common in AWMI as compared to IWMI patients (Table I).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>52±12</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>56/32</td>
</tr>
<tr>
<td>RWMA (Ant/Inf)</td>
<td>59/29</td>
</tr>
<tr>
<td>Thrombolysis (%)</td>
<td>82.9</td>
</tr>
<tr>
<td>Dyslipidaemia (%)</td>
<td>60</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>57</td>
</tr>
<tr>
<td>Diabetes Mellitus (%)</td>
<td>42</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>28</td>
</tr>
<tr>
<td>Alcohol (%)</td>
<td>51</td>
</tr>
</tbody>
</table>

Table I: Clinical and Biochemical Characteristics of the Study Group

Fig. 1: Sex Distribution of My Study Population

Fig. 2: Thrombolysed Cases

Fig. 3: Clinical Profile of My Study Population
When we assessed the relationship between cTnT and the indices of LV function obtained by Echocardiography performed at the time of ICCU discharge, cTnT was inversely correlated with LVEF ($r = -0.4864$; $P < 0.0001$; Fig. 5).

Table II shows the relation between cTnT and LVEF. There was a strong negative correlation between cTnT level and Echocardiographic LVEF. The Pearson’s correlation coefficient between cTnT and LVEF was $r = -0.4864$ (Fig. 5). The cTnT value was high among patients with LVEF <50%, which was statistically significant ($p < 0.0001$).

Analysis by ROC curve produced an area under the curve of 0.945 (95% CI 0.875 to 0.982) at a cut-off left ventricular ejection fraction of 50% (Fig. 18). A troponin concentration of > 3.24 μg/mL predicted a left ventricular ejection fraction of < 50% with a sensitivity of 91.67% (CI 80 to 97.7) and specificity of 92.5% (CI 79.6 to 98.4).

The result of re-analysis to examine the effect of reperfusion by excluding 15 patients who did not receive thrombolysis was no different from analysis of all patients. Table IV shows the sensitivity and specificity of cTnT to predict LVEF. It was found that cTnT concentration > 3.24 μg/mL predicted LVEF of < 50% with a sensitivity of 91.67% and specificity of 92.5%.

Table IV shows the relation between QRS Score and LVEF. There was a negative correlation between QRS score and LVEF. The Pearson’s correlation coefficient between QRS Score and LVEF was $r = -0.5834$ (Fig. 6). The QRS Score was high among patients with LV EF < 50%, which was statistically significant ($p < 0.0001$)
Table IV: QRS Score (Mean ± SD) in Relation to Ejection Fraction

<table>
<thead>
<tr>
<th>Ejection Fraction</th>
<th>N</th>
<th>QRS Score (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 50%</td>
<td>47</td>
<td>5.8 ± 2.7</td>
</tr>
<tr>
<td>≥ 50%</td>
<td>41</td>
<td>2.4 ± 2.1</td>
</tr>
</tbody>
</table>

Table IV: QRS Score (Mean ± SD) in Relation to Ejection Fraction

Analysis by ROC curve produced an area under the curve of 0.831 (95% CI 0.736 to 0.903) at a cut-off left ventricular ejection fraction of 50% (Fig. 20). The QRS Score of > 6 predicted a left ventricular ejection fraction of < 50% with a sensitivity of 79.2% (CI 65 to 89.5) and specificity of 70.2% (CI 53.5 to 83.4).

Table V shows the sensitivity and specificity of QRS Score to predict LVEF. It was found that QRS Score > 6 predicted LVEF of < 50% with a sensitivity of 79.2% and specificity of 70.2%.

Table V: QRS Score and Ejection Fraction

<table>
<thead>
<tr>
<th>QRS Score</th>
<th>EF &lt; 50%</th>
<th>EF &gt; 50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 6</td>
<td>43(a)</td>
<td>19(b)</td>
</tr>
<tr>
<td>&lt; 6</td>
<td>4(c)</td>
<td>22(d)</td>
</tr>
</tbody>
</table>

DISCUSSION

Serum troponin T is accepted as a highly reliable biochemical marker for detecting myocardial damage and its use in the diagnosis of acute myocardial infarction is increasing.

Data show that serum troponin T is related to the amount of myocardial damage. But the relation between serum troponin T and impairment of left ventricular function after acute myocardial infarction has not been examined.

This study shows a strong negative correlation between serum troponin T concentration measured 12–48 hours post-myocardial infarction and echocardiographic left ventricular ejection fraction (r = -0.4864; p < 0.0001).

Analysis of the relation between troponin T and Echocardiographic left ventricular ejection fraction by ROC curve shows that a troponin T concentration of >3.24 μg/mL is a sensitive (91.67%) and specific (92.5%) indicator of a left ventricular ejection fraction of < 50% after a first myocardial infarction.

The result of re-analysis to examine the effect of reperfusion by excluding 15 patients who did not receive thrombolysis was no different from analysis of all patients.

Troponin T has practical advantages over other markers in the assessment of left ventricular ejection fraction. After acute infarction troponin T has a peak value at 12 hours from the onset of pain, if successful reperfusion has occurred corresponding to washout of the cytoplasmic fraction. The plateau phase of troponin T, however, lasts up to 48 hours and represents an integrated estimate of myocyte necrosis. The peak value will therefore be missed in samples taken 12–48 hours after admission, but there is a large time window. This makes repeated sampling unnecessary and represents a cost and time effective method of diagnosis and quantification.

This is in contrast to creatine kinase MB or myoglobin for which multiple measurements are required and whose values are affected by thrombolysis.

In our study, cTnT levels closely correlated with Echocardiographic Ejection Fraction. Our results corroborate those of earlier clinical studies in which cTnT release, not a single-point measurement was used to assess infarct size.

Furthermore, our findings in living patients are consistent with those obtained experimentally in dogs by Remppis et al(17) who found a good correlation (r 0.69; P 0.003; n 16) between cTnT concentrations 96 hrs. after the onset of ischaemia and the pathoanatomic infarct size as quantified by the 2,3, 5-triphenyltetrazolium chloride method.
In clinical practice, estimation of AMI size based on cTnT determination on a single plasma sample at CCU would facilitate the choice of appropriate care, leading to more efficient and economic use of healthcare facilities. This approach appears to be more useful than analysing cumulative cTnT release, as proposed previously because of the requirement of repetitive sampling and a possible incomplete recovery of cTnT.

LVEF is a very powerful prognostic indicator after AMI. A strong inverse relationship exists between LV function and patient outcome with rapidly increasing mortality rates at LVEFs 40%.

Rao et al. first showed a good correlation between cTnT concentrations measured 12–48 hrs. after admission and LVEF (r=0.72; P 0.001; n 50). In the study, a cTnT 2.8 g/L predicted an LVEF 40% with a sensitivity of 100% and specificity of 93% (Area under the ROC curve, 0.98).

Kanna et al. confirmed that serum cTnT on day 3 or 4 after AMI was significantly negatively correlated with LVEF assessed 1 month later (r=0.48; P 0.001; n 86).

Panteghini et al. demonstrated a significant inverse relationship between LVEF derived from gated SPECT and plasma cTnT (r=0.56; P 0.001; n 65).

In this study, we got a significant correlation between QRS score and echocardiographic ejection fraction measured at the time of hospital discharge. There was a negative correlation between QRS Score and LVEF. The Pearson’s correlation coefficient between QRS score and LVEF was r=-0.5834. The QRS Score was high among patients with LVEF <50%, which was statistically significant (p < 0.0001). The QRS Score of > 6 predicted a left ventricular ejection fraction of < 50% with a sensitivity of 79.2% (CI 65 to 89.5) and specificity of 70.2% (CI 53.5 to 83.4).

As expected, the QRS score is also related to estimates of left ventricular damage made by cardiac markers. Because QRS score correlates well with left five-year survival rate of 88% patients with a score of 10 or more had survival rates of 81 and 52% respectively at the same intervals.

The advantage of the QRS score is that it is calculated from a routine 12-lead electrocardiogram. It can be derived without risk in any patient who does not have left ventricular hypertrophy or conduction defects.

The QRS scoring system, which takes into account the duration and amplitude ratios of the QRS complex appears to be a better predictor of ejection fraction.

In this study, we used the QRS score in patients with a first infarction; it is still unclear whether it is as useful in patients who have had more than one infarction.

CONCLUSION

Serum troponin-T concentration has a strong negative correlation with left ventricular ejection fraction after first acute myocardial infarction, and hence can be used to assess the LVEF in patients with first myocardial infarction. A level of >3.24 µg/mL provided a good indication for LVEF below 50% with a sensitivity of 91.67% (CI 80 to 97.7) and specificity of 92.5% (CI 79.6 to 98.4) and thus can identify patients with high risk.

A significant negative correlation was observed between the QRS score obtained at the time of discharge and left ventricular ejection fraction (r =-0.5834). The QRS Score was high among patients with LVEF <50% that is in patients with a QRS score ≥6. Left Ventricular Ejection Fraction was found to be <50% with sensitivity of 79.2 and specificity of 70.2%.

REFERENCES


